MEK inhibitors both upregulate programmed death ligand 1 (PD-L1) expression in mouse-derived TNBC cell lines and promote recruitment of TILs to the tumor, and combined treatment with MEK inhibitors and immune checkpoint inhibitors enhanced antitumor immune response in mouse models [160]. Here, MAP2K7 is linked to neoplasm.